Abivax Banks on Market Potential for Drug Candidate Obefazimod

Like
Comment
Favorite

Abivax Banks on Market Potential for Drug Candidate Obefazimod

MT Newswires Live01-08

Abivax SA (ABVX) reported late Wednesday significant market potential for its lead drug candidate, obefazimod, for ulcerative colitis, amid continued progress in its late-stage trials.

The bio-tech company said the ABTECT Phase 3 Data Safety Monitoring Board last month found no new safety signals for the drug in the treatment of moderate-to-severely active ulcerative colitis.

Topline results from the ABTECT Phase 3 trial are expected in the late second quarter.

Meanwhile, induction results from the ongoing ENHANCE-CD Phase 2b trial of obefazimod for moderate-to-severely active Crohn's disease are set to come in late 2026.

Abivax expects its cash runaway to extend into the fourth quarter of fiscal 2027, following full debt reimbursement in the fourth quarter of fiscal 2025.

Shares fell more than 1% in recent after-hours trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2601938111?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 05:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601938111","market":"hk","top_or_hot":-1,"title":"Abivax Banks on Market Potential for Drug Candidate Obefazimod","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/AAVXF\">Abivax SA</a> (ABVX) reported late Wednesday significant market potential for its lead drug candidate, obefazimod, for ulcerative colitis, amid continued progress in its late-stage trials.</p><p>The bio-tech company said the ABTECT Phase 3 Data Safety Monitoring Board last month found no new safety signals for the drug in the treatment of moderate-to-severely active ulcerative colitis.</p><p>Topline results from the ABTECT Phase 3 trial are expected in the late second quarter.</p><p>Meanwhile, induction results from the ongoing ENHANCE-CD Phase 2b trial of obefazimod for moderate-to-severely active Crohn's disease are set to come in late 2026.</p><p>Abivax expects its cash runaway to extend into the fourth quarter of fiscal 2027, following full debt reimbursement in the fourth quarter of fiscal 2025.</p><p>Shares fell more than 1% in recent after-hours trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abivax Banks on Market Potential for Drug Candidate Obefazimod</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbivax Banks on Market Potential for Drug Candidate Obefazimod\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-08 05:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/AAVXF\">Abivax SA</a> (ABVX) reported late Wednesday significant market potential for its lead drug candidate, obefazimod, for ulcerative colitis, amid continued progress in its late-stage trials.</p><p>The bio-tech company said the ABTECT Phase 3 Data Safety Monitoring Board last month found no new safety signals for the drug in the treatment of moderate-to-severely active ulcerative colitis.</p><p>Topline results from the ABTECT Phase 3 trial are expected in the late second quarter.</p><p>Meanwhile, induction results from the ongoing ENHANCE-CD Phase 2b trial of obefazimod for moderate-to-severely active Crohn's disease are set to come in late 2026.</p><p>Abivax expects its cash runaway to extend into the fourth quarter of fiscal 2027, following full debt reimbursement in the fourth quarter of fiscal 2025.</p><p>Shares fell more than 1% in recent after-hours trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601938111","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601938111","pubTimestamp":1767822714,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Abivax SA  reported late Wednesday significant market potential for its lead drug candidate, obefazimod, for ulcerative colitis, amid continued progress in its late-stage trials.The bio-tech company said the ABTECT Phase 3 Data Safety Monitoring Board last month found no new safety signals for the drug in the treatment of moderate-to-severely active ulcerative colitis.Topline results from the ABTECT Phase 3 trial are expected in the late second quarter.Meanwhile, induction results from the ongoing ENHANCE-CD Phase 2b trial of obefazimod for moderate-to-severely active Crohn's disease are set to come in late 2026.Abivax expects its cash runaway to extend into the fourth quarter of fiscal 2027, following full debt reimbursement in the fourth quarter of fiscal 2025.Shares fell more than 1% in recent after-hours trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ABVX":"Abivax S.A."},"translate_title":"Abivax看好候选药物Obefazimod的市场潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"Abivax SA (ABVX) reported late Wednesday significant market potential for its lead drug candidate, obefazimod, for ulcerative colitis, amid continued progress in its late-stage trials.The bio-tech company said the ABTECT Phase 3 Data Safety Monitoring Board last month found no new safety signals for the drug in the treatment of moderate-to-severely active ulcerative colitis.Topline results from the ABTECT Phase 3 trial are expected in the late second quarter.Meanwhile, induction results from the ongoing ENHANCE-CD Phase 2b trial of obefazimod for moderate-to-severely active Crohn's disease are set to come in late 2026.Abivax expects its cash runaway to extend into the fourth quarter of fiscal 2027, following full debt reimbursement in the fourth quarter of fiscal 2025.Shares fell more than 1% in recent after-hours trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}